Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Objective The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, it is important to determine whether glucose-lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in patients with type 2 diabetes tr...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cardiovascular diabetology Ročník 14; číslo 1; s. 116
Hlavní autori:	Simó, Rafael, Guerci, Bruno, Schernthaner, Guntram, Gallwitz, Baptist, Rosas-Guzmàn, Juan, Dotta, Francesco, Festa, Andreas, Zhou, Ming, Kiljański, Jacek
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 04.09.2015
Predmet:	Aged Angiology Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Blood Pressure - drug effects C-Reactive Protein - metabolism Cardiology Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - etiology Cardiovascular Diseases - physiopathology Cardiovascular Diseases - prevention & control Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Drug Administration Schedule Drug Therapy, Combination Europe Exenatide Female Glycated Hemoglobin - metabolism Heart Rate - drug effects Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Incretins - administration & dosage Incretins - adverse effects Lipids - blood Male Medicine Medicine & Public Health Metformin - administration & dosage Middle Aged Original Investigation Peptides - administration & dosage Peptides - adverse effects Risk Factors Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - adverse effects Time Factors Treatment Outcome Venoms - administration & dosage Venoms - adverse effects Type 2 diabetes Exenatide twice daily High-sensitivity C-reactive protein GLP-1 receptor agonist Cardiovascular risk
ISSN:	1475-2840, 1475-2840
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!